Tags

Type your tag names separated by a space and hit enter

Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Urology. 2011 Sep; 78(3):636-40.U

Abstract

OBJECTIVE

To compare the efficacy of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg and tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

METHODS

Data were analyzed from a prospective, multicenter, randomized, open, parallel study of Chinese men aged 50-84 years with LUTS/BPH. Two hundred patients were randomized to receive daily treatment with 4 mg doxazosin-GITS (n=100) or 0.2 mg tamsulosin (n=100) for 8 weeks. Nocturia was assessed by question 7 of the International Prostate Symptom Score (IPSS-question 7) and a frequency-volume chart (FVC) at weeks 4 and 8. Self-reported quality of sleep and quality of life by the last question of the IPSS questionnaire were also evaluated.

RESULTS

A total of 189 patients (94 receiving doxazosin-GITS, 95 tamsulosin) completed the study. The reduction from baseline in mean nocturia was greater with doxazosin-GITS than tamsulosin by the FVC (1.7 vs 1.3 at week 4; 2.1 vs 1.7 at week 8, both P=.001) and by the IPSS-question 7 (1.5 vs 1.1 at 4 weeks, P=.001; 2.0 vs 1.6 at 8 weeks, P<.001). The patients who reported improved quality of sleep was significantly more with doxazosin-GITS than tamsulosin (43.6% vs 27.4% at 4 weeks, P=.020; 81.9% vs 67.4% at 8 weeks, P=.022), and quality of life was better with doxazosin-GITS (2.5 vs 2.8 at 4 weeks, P=.001; 2.1 vs 2.5 at 8 weeks, P<.001).

CONCLUSION

In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia.

Authors+Show Affiliations

Department of Urology, Peking University, First Hospital, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

21696807

Citation

Zhang, Kai, et al. "Effect of Doxazosin Gastrointestinal Therapeutic System 4 Mg Vs Tamsulosin 0.2 Mg On Nocturia in Chinese Men With Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study." Urology, vol. 78, no. 3, 2011, pp. 636-40.
Zhang K, Yu W, Jin J, et al. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. Urology. 2011;78(3):636-40.
Zhang, K., Yu, W., Jin, J., Ye, H., Wang, X., Zhang, N., Yang, Y., Zhong, C., & Wan, B. (2011). Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. Urology, 78(3), 636-40. https://doi.org/10.1016/j.urology.2011.04.038
Zhang K, et al. Effect of Doxazosin Gastrointestinal Therapeutic System 4 Mg Vs Tamsulosin 0.2 Mg On Nocturia in Chinese Men With Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study. Urology. 2011;78(3):636-40. PubMed PMID: 21696807.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. AU - Zhang,Kai, AU - Yu,Wei, AU - Jin,Jie, AU - Ye,Haiyun, AU - Wang,Xiaofeng, AU - Zhang,Ning, AU - Yang,Yong, AU - Zhong,Chenyang, AU - Wan,Ben, Y1 - 2011/06/21/ PY - 2011/03/15/received PY - 2011/04/18/revised PY - 2011/04/21/accepted PY - 2011/6/24/entrez PY - 2011/6/24/pubmed PY - 2011/11/9/medline SP - 636 EP - 40 JF - Urology JO - Urology VL - 78 IS - 3 N2 - OBJECTIVE: To compare the efficacy of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg and tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). METHODS: Data were analyzed from a prospective, multicenter, randomized, open, parallel study of Chinese men aged 50-84 years with LUTS/BPH. Two hundred patients were randomized to receive daily treatment with 4 mg doxazosin-GITS (n=100) or 0.2 mg tamsulosin (n=100) for 8 weeks. Nocturia was assessed by question 7 of the International Prostate Symptom Score (IPSS-question 7) and a frequency-volume chart (FVC) at weeks 4 and 8. Self-reported quality of sleep and quality of life by the last question of the IPSS questionnaire were also evaluated. RESULTS: A total of 189 patients (94 receiving doxazosin-GITS, 95 tamsulosin) completed the study. The reduction from baseline in mean nocturia was greater with doxazosin-GITS than tamsulosin by the FVC (1.7 vs 1.3 at week 4; 2.1 vs 1.7 at week 8, both P=.001) and by the IPSS-question 7 (1.5 vs 1.1 at 4 weeks, P=.001; 2.0 vs 1.6 at 8 weeks, P<.001). The patients who reported improved quality of sleep was significantly more with doxazosin-GITS than tamsulosin (43.6% vs 27.4% at 4 weeks, P=.020; 81.9% vs 67.4% at 8 weeks, P=.022), and quality of life was better with doxazosin-GITS (2.5 vs 2.8 at 4 weeks, P=.001; 2.1 vs 2.5 at 8 weeks, P<.001). CONCLUSION: In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia. SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/21696807/Effect_of_doxazosin_gastrointestinal_therapeutic_system_4_mg_vs_tamsulosin_0_2_mg_on_nocturia_in_Chinese_men_with_lower_urinary_tract_symptoms:_a_prospective_multicenter_randomized_open_parallel_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(11)00439-0 DB - PRIME DP - Unbound Medicine ER -